Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we...
New emerging RNA-based therapies targeting apo(a) production achieve reductions in Lp(a) up to 90%; however, they have not yet been approved and there is no evidence that reducing Lp(a) decreases ASCVD outcomes [3,6]. These facts have been considered by different international clinical ...
The risk of serious side effects range from one in 500 to one in 1,000, which is considered very low. Muscle aches are a possible side effect, but are not considered serious. An increase in the dose of statins is not associated with an increase in side effect...
Technically geater than/equal to 130 systolic or diastolic equal to 80-89 is considered Stage I Hypertension based on the new guidelines. Stage I suggests medication therapy only if: “patient has already had a cardiovascular event such as a heart attack or stroke, or is at high risk of hea...
LDIS LDISD LDIT LDIWG LDJ LDJIN LDK LDKA LDKB LDKM LDKP LDKT LDL LDL-C LDL-RD LDL/VLDL LDL1 LDL2 LDLA LDLB LDLC LDLE LDLG LDLL LDLLT LDLM LDLN LDLo LDLP LDLPS LDLR LDLrs LDLS LDLT LDLTP LDLV LDM LDMA LDMC LDMCF ...